Literature DB >> 1627658

Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.

K Ziegler1, W Stünkel.   

Abstract

Pravastatin is a foreign substrate of a sodium-independent transport system for bile acids. The tissue selectivity of pravastatin in inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase is due to the uptake via a transport system which exists predominantly in liver cells. Pravastatin competitively inhibits the sodium-independent hepatocellular uptake of cholate, taurocholate and ouabain, whereas the total uptake of cholate is non-competitively blocked. The affinity of pravastatin to the sodium-dependent taurocholate transporter is, however, low. Millimolar concentrations of pravastatin are needed to inhibit the sodium-taurocholate cotransporter. Pravastatin has no affinity to other transport systems in liver cells such as those for long-chain fatty acids, amino acids, rifampicin and bivalent organic cations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627658     DOI: 10.1016/0925-4439(92)90135-a

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

2.  Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats.

Authors:  M Yamazaki; S Akiyama; R Nishigaki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.

Authors:  T Tokui; D Nakai; R Nakagomi; H Yawo; T Abe; Y Sugiyama
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 5.  Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Authors:  Yiannis S Chatzizisis; Konstantinos C Koskinas; Gesthimani Misirli; Christos Vaklavas; Apostolos Hatzitolios; George D Giannoglou
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 6.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 7.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.

Authors:  David G Menter; Victoria P Ramsauer; Sam Harirforoosh; Kanishka Chakraborty; Peiying Yang; Linda Hsi; Robert A Newman; Koyamangalath Krishnan
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.